Seer Sets Conservative 2026 Guidance After Q4 Revenue Miss from NIH Funding Delays
Seer reported Q4 2025 revenue growth but missed expectations due to NIH funding delays prompting customer order postponements. Management set conservative 2026 revenue guidance citing uncertain funding environment while pursuing large cohort population-scale studies and expanding instrument placements to drive future upside.
1. Q4 Financial Performance
Seer reported strong revenue growth in Q4 2025 but fell short of internal targets after delayed NIH funding led several customers to defer planned instrument purchases originally scheduled for the quarter.
2. 2026 Guidance Outlook
Management issued conservative revenue guidance for FY 2026, highlighting an uncertain funding environment as the primary risk, despite ongoing momentum in instrument placements and consumable volume growth.
3. Technology Adoption and Feedback
Beyond funding constraints, the main challenge remains transitioning customers from targeted to untargeted proteomics; positive user feedback is accumulating through an increasing number of publications and diagnostic tests leveraging Seer's platform.
4. Upside from Population-Scale Studies
Seer is in discussions with several large cohorts for population-scale studies that could exceed current guidance if agreements close, while continuing to expand its installed instrument base to drive long-term growth.